NASDAQ: QSIQuantum Si Inc Stock
$0.89-0.04 (-4.3%)
Updated May 15, 2026
QSI Price
$0.89
Fair Value Price
-$0.03
Market Cap
$193.81M
52 Week Low
$0.69
52 Week High
$3.10
P/E
-1.78x
P/B
0.97x
P/S
90.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.85M
Earnings
-$103.82M
Gross Margin
40%
Operating Margin
-5,609.94%
Profit Margin
-5,605.9%
Debt to Equity
0.06
Operating Cash Flow
-$94M
Beta
2.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QSI Overview
Quantum-Si incorporated, a life sciences company, offers a single molecule detection platform that enables nextgen protein sequencing and is used in DNA applications. Quantum-Si was incorporated in 2013 is based in Guilford, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QSI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
QSI
Ranked#326 of 462
Ranked#326 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $228.77 | A | |
| $50.13 | A | |
| $1.98 | A |
Be the first to know about important QSI news, forecast changes, insider trades & much more!
QSI News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QSI ($0.89) is overvalued by 3,543.13% relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QSI ($0.89) is not significantly undervalued (3,543.13%) relative to our estimate of its Fair Value price of -$0.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QSI due diligence checks available for Premium users.
Valuation
QSI fair value
Fair Value of QSI stock based on Discounted Cash Flow (DCF)
Price
$0.89
Fair Value
-$0.03
Undervalued by
3,543.13%
QSI ($0.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QSI ($0.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.78x
Industry
16.99x
Market
22.65x
QSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
4.84x
QSI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QSI's financial health
Profit margin
Revenue
$258.0k
Net Income
-$21.7M
Profit Margin
-8,399.6%
QSI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QSI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$213.3M
Liabilities
$12.6M
Debt to equity
0.06
QSI's short-term assets ($134.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QSI's short-term assets ($134.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.6M
Investing
$40.3M
Financing
$0.0
QSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QSI vs Biotech Stocks
Quantum Si Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.